<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455091</url>
  </required_header>
  <id_info>
    <org_study_id>T1206</org_study_id>
    <nct_id>NCT00455091</nct_id>
  </id_info>
  <brief_title>A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma</brief_title>
  <official_title>A Randomization Trial of Adjuvant Lamivudine/ Adefovir Dipivoxil Against Recurrence in Post-operative HBV-related Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research Objective and Study End Points To evaluate the anti-HBV as well as HCC recurrence&#xD;
      reducing effects of standard (18 months) lamivudine treatment at time of HBV reactivation&#xD;
      with hepatitis flare up (HBV DNA &gt; 105 copies/mL and ALT level &gt; 2.0 x UNL) or prophylactic,&#xD;
      prolong (36 months) adefovir dipivoxil therapy in post-operative HBsAg(+),&lt; 5 cm HCC&#xD;
      patients, and to compare the results of who group with historical controls (T1297, HBsAg+,&lt; 5&#xD;
      cm HCC cohort),in terms of the following endpoints.&#xD;
&#xD;
        1. Primary endpoint:&#xD;
&#xD;
           the 3-years recurrence rate (excluding those recur within first year).&#xD;
&#xD;
        2. Secondary endpoints:&#xD;
&#xD;
      the first 2 year tumor recurrence rates the recurrence-free survival the overall survival.&#xD;
      anti-viral efficacy, i.e. biochemical response and viral response rate. to correlate the&#xD;
      changes of viral titer with the clinical outcome in post- operative HCC patients with&#xD;
      adjuvant lamivudine or adefovir therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment plan and Randomization scheme:&#xD;
&#xD;
      HBsAg+, HCC&lt; 5 cm with curative resection Stratified with HBV DNA &lt; 105 OR â‰¥ 105 copies/mL&#xD;
      Genotype B or C RANDOMIZATION Prophylactic group Therapeutic control group Adefovir Dipivoxil&#xD;
      10mg/day x 36 months Lamivudine 100 mg/day x 18 months#, when HBV DNA =/&gt; 105 copies/mL and&#xD;
      ALT &gt; 2.0 x UNL&#xD;
&#xD;
        -  When YMDD mutant present, switch to Adefovir dipivoxil 10mg/day x 24 months. Selection&#xD;
           of patients&#xD;
&#xD;
             1. Eligibility Criteria (1)Histologically proven hepatocellular carcinoma. (2)HCC&#xD;
                underwent curative resection within 6 weeks before registration. (3)Grossly, the&#xD;
                resection margin should be &gt; 1 cm. (4)Tumors, either single, &lt; 5 cm in size or no&#xD;
                more than 3 for size &lt; 3 cm. (5)Patients must have a performance status of ECOG&#xD;
                score &lt; 2. (6)Patients must have adequate liver reservation and adequate hemogram.&#xD;
                (i)Pugh-Child's Score &lt; 7. (ii)The serum total bilirubin level are &lt; 2 mg/dl.&#xD;
                (iii)The prothrombin times are &lt; 3 sec above normal control. (iv)The platelet are &gt;&#xD;
                7.5 x 104 / mm3. (v)The WBC are &gt; 3,000 / mm3. (7)Patient must have serum&#xD;
                creatinine &lt; 1.5 mg/dl (8)Cardiac function with NYHA classification &lt; Grade II&#xD;
                (9)HBsAg (+) . (10)Signed informed consent.&#xD;
&#xD;
             2. Ineligibility Criteria&#xD;
&#xD;
             1. Patients who have non-curative resection are not eligible.&#xD;
&#xD;
             2. Resected HCCs with histologically positive margins are not eligible.&#xD;
&#xD;
             3. HCCs with radiological evidence of portal vein thrombus are not eligible.&#xD;
&#xD;
             4. Patients with other systemic diseases which required concurrent usage of&#xD;
                glucoticosteroid or immunosuppressant agent(s) are not eligible.&#xD;
&#xD;
             5. Patients with advanced second primary malignancy are not eligible.&#xD;
&#xD;
             6. Patients with pregnancy or breast-feeding are not eligible.&#xD;
&#xD;
             7. Patients with severe cardiopulmonary diseases are not eligible.&#xD;
&#xD;
             8. Patients with clinically significant psychiatric disorder are not eligible.&#xD;
&#xD;
             9. Patients who had antineoplastic chemotherapeutic or immuno-therapeutic drugs or&#xD;
                corticosteroids within 6 weeks of commencing the protocol are not eligible.&#xD;
&#xD;
            10. Patients who had prior lamividine and/or adefovir dipivoxil therapy are not&#xD;
                eligible.&#xD;
&#xD;
            11. Anti-HCV positive patients are not eligible. Statistical Consideration&#xD;
&#xD;
                Sample size:&#xD;
&#xD;
                With a phase III superior study design, to give an 80% power with a two-sided 5%&#xD;
                significance level, 139 patients per each treatment arm should be included in the&#xD;
                study. If a 10% drop-out rate is included, totally, 309 patients (155 per study&#xD;
                arm) will be required.&#xD;
&#xD;
                Analysis&#xD;
&#xD;
                The objectives are as follows:&#xD;
&#xD;
           1.Primary endpoint: the 3-year recurrence rate (excluding those recur within 1st year)&#xD;
&#xD;
             1. Second endpoints the recurrence-free survival.&#xD;
&#xD;
             2. Second endpoints: the overall survival.&#xD;
&#xD;
             3. Second endpoints: anti-viral efficacy, in terms of sustained biochemical response&#xD;
                rate and viral response rate. To correlate the changes of viral titer with the&#xD;
                clinical outcome 2 RFS and OS are computed from the date of randomization.&#xD;
&#xD;
           (1) In analysis of RFS, patients died without disease recurrence will be censored for&#xD;
           recurrence at the date of death (2) In analysis of OS, an event is defined as death from&#xD;
           any cause. (3) The survival distributions of RFS and OS will be estimated by the Kaplan&#xD;
           and Meier method.&#xD;
&#xD;
           (4) Statistical comparisons of RFS and OS between the two treatment arms will be&#xD;
           performed with the log-rank test.&#xD;
&#xD;
           (5) Cox proportional hazards model will be used to assess the importance of potential&#xD;
           prognostic factors, as well as to test the significance of treatment when adjusting for&#xD;
           factors [39].&#xD;
&#xD;
           3.Tumor size, Liver inflammation, viral status, i.e. HBV genotype and DNA titer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No cases enrollment&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: Primary endpoint: the 3-years recurrence rate (excluding those recur within first year).</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints: the first 2 year tumor recurrence rates,the recurrence-free survival,the overall survival.anti-viral efficacy.</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">117</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil and Lamivudine</intervention_name>
    <description>Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/&gt; 105 copies/mL and ALT &gt; 2.0 x UNL</description>
    <other_name>Hepsera,Zeffix</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      HBVDNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Post-operative HBV-related Hepatocellular Carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven hepatocellular carcinoma.&#xD;
&#xD;
          2. HCC underwent curative resection within 6 weeks before registration.&#xD;
&#xD;
          3. Grossly, the resection margin should be &gt; 1 cm.&#xD;
&#xD;
          4. Tumors, either single, &lt; 5 cm in size or no more than 3 for size &lt; 3 cm.&#xD;
&#xD;
          5. Patients must have a performance status of ECOG score &lt; 2.&#xD;
&#xD;
          6. Patients must have adequate liver reservation and adequate hemogram.&#xD;
&#xD;
               -  Pugh-Child's Score &lt; 7.&#xD;
&#xD;
               -  The serum total bilirubin level are &lt; 2 mg/dl.&#xD;
&#xD;
               -  The prothrombin times are &lt; 3 sec above normal control.&#xD;
&#xD;
               -  The platelet are &gt; 7.5 x 104 / mm3.&#xD;
&#xD;
               -  The WBC are &gt; 3,000 / mm3.&#xD;
&#xD;
          7. Patient must have serum creatinine &lt; 1.5 mg/dl&#xD;
&#xD;
          8. Cardiac function with NYHA classification &lt; Grade II&#xD;
&#xD;
          9. HBsAg (+) .&#xD;
&#xD;
         10. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have non-curative resection are not eligible.&#xD;
&#xD;
          2. Resected HCCs with histologically positive margins are not eligible.&#xD;
&#xD;
          3. HCCs with radiological evidence of portal vein thrombus are not eligible.&#xD;
&#xD;
          4. Patients with other systemic diseases which required concurrent usage of&#xD;
             glucoticosteroid or immunosuppressant agent(s) are not eligible.&#xD;
&#xD;
          5. Patients with advanced second primary malignancy are not eligible.&#xD;
&#xD;
          6. Patients with pregnancy or breast-feeding are not eligible.&#xD;
&#xD;
          7. Patients with severe cardiopulmonary diseases are not eligible.&#xD;
&#xD;
          8. Patients with clinically significant psychiatric disorder are not eligible.&#xD;
&#xD;
          9. Patients who had antineoplastic chemotherapeutic or immuno-therapeutic drugs or&#xD;
             corticosteroids within 6 weeks of commencing the protocol are not eligible.&#xD;
&#xD;
         10. Patients who had prior lamividine and/or adefovir dipivoxil therapy are not eligible.&#xD;
&#xD;
         11. Anti-HCV positive patients are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Tzong Chen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pei-Jer Chen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miin-Fu Chen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital-Kaohsiung</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital (Lin-Kou)</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital-Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-operative Hepatocellular Carcinoma.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

